Scientists dig into DNA of Kids' moles to unlock melanoma secrets
NCT ID NCT02775643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects tumor samples from 500 children and teens with melanoma or related skin growths to analyze their genetic makeup. Researchers aim to learn more about what drives these rare childhood cancers. No new treatments are being tested; instead, the focus is on gathering molecular data to guide future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal key genetic differences in childhood melanoma, pointing toward better diagnosis or future treatments.
- What could go wrong
- This is an observational study, not testing a treatment. It may not directly lead to new therapies, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2016
- Expected to finish
-
May 2041
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants who meet inclusion criteria and consent to enrollment on the study at St. Jude Children's Research Hospital (SJCRH).
- Ages
-
Up to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant has a suspected or confirmed diagnosis of a melanocytic lesion, including: * Conventional or "adult-type" melanoma * Spitzoid melanoma/atypical Spitz tumor * Congenital melanoma * Melanoma arising in a giant congenital nevus * Melanocytic lesions with indeterminate biological behavior (e.g., pigment synthesizing melanomas) * Participant was \<19 years of age at the time of diagnosis. * Tissue is available for biologic studies. * Participant has been enrolled on the TBANK protocol at SJCRH, or will be enrolled before any research tests are performed on their biological materials. Exclusion Criteria: * Ocular melanoma * Inability or unwillingness of research participant or legal guardian to consent. * Histologic diagnosis other than melanocytic lesion described in 3.1.1.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Melanoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Blood test could spot Melanoma's BRAF mutation
- Can a CXCR1/2 blocker boost radiation against cancer that spreads to the brain lining?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can tumor DNA and immune cells reveal why some cancers resist immunotherapy?
- Can a Two-Drug immune combo shrink melanoma tumors?